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Identity 
Other names: CCS-3; CCS3; EEF-1; EEF1A; EF-1-; 
alpha-1; EF-Tu; EF1A; FLJ25721; RAF-1EF; LENG7; 
MGC102687; MGC131894; MGC16224; PTI1; 
eEF1A-1 
HGNC (Hugo): EEF1A1 
Location: 6q13 




8 exons, 7 introns (1st intron within 5'UTR), plus a rare 
optional exon within first intron as found in several 
ESTs (e.g. emb-CR981691.1, dbj-DC388133.1, dbj-
DC406334.1). 
Presumably a second promoter, about 800 nt upstream 
of the most common transcription start, provides an 
alternative first exon about 320 nt long, as deduce 
from some ESTs at NCBI (e.g. dbj-DC316623.1, gb-
BU173251.1, dbj-DC358918.1). 
Introns number 2, 3, 4, 6 are phase 0 (between codons), 
Introns number 5, 7 are phase 1 (between 1st and 2nd 
base of codon). 
A validated C-G non-synonimous polymorphism has 
been reported at 1st position of codon 382 (Arg-Gly), 
plus a few single-hit non-synonimous and some 
synonymous within CDS. Several others within 3'UTR 
and introns (SNP source). 
Transcription 
The main processed mRNA encompasses exons 1, 2, 3, 
4, 5, 6, 7, 8, this last can be in short or long form. In a 
few cases also exon 1' is retained. In a few cases exons 
1 (and 1') are substituted by the alternative exon fr m a 
putative upstream minor promoter, as described above. 
Moreover, a quite high number of processed transcripts 
that, after exons 1 and 2, retain intron 2, which 
introduces a stop codon 22 residues downstream of 
exon 2 are found (see for instance some of the many 
ESTs: dbj-DC389722.1, dbj-DC341899.1, dbj-
DC414491.1). 
Pseudogene 
About 20 complete or approximately complete 
intronless pseudogenes, likely generated by retro-
transposition, a few of them exempt from frameshifs 
and with only a few missenses, are present throughout 
the genome. Two of them harbour a few hundreds nt 
long insert each, not related to introns of the expr ssed 
gene. 
All of them show a higher homology to EEF1A1 than 
to EEF1A2. Most of the pseudogenes find an 
orthologous counterpart within the chimpanzee 
genome. 
EEF1AL3 (9q34) Note: highly homologous; EEF1AL4 
(7p15.3) Note: highly homologous but with 1 
frameshift; EEF1AL5-LOC390924 (19q13.12) Note: 
contains a 502 nt insert; EEF1AL6 (3q27.1); EEF1AL7 
(4q24); EEF1AL8- 
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Box = exon (blue = 5'UTR, yellow = CDS, light blue = rare optional exon, red = 3'UTR, light red = extended 3'UTR to a downstream polyA 
signal) Line = intron. 
 
Upper boxes, alternating colours: exons (coding part only). Lower boxes: protein domains. 
 
LOC100132804 (7q35); EEF1AL9 (1p21.3); 
EEF1AL10-LOC644604 (2q12); EEF1AL11 (5p15.1) 
Note: rather highly homologous; EEF1AL12-
LOC647167 (1q31.3); EEF1AL13-LOC100130211 
(Xq21.2) Note: lacking about 300 initial codifying nt; 
LOC124199 (16p12.1) Note: contains a 307 nt insert; 
LOC387845 (12p12.3); LOC389223 (4q28.3); 
LOC401717 (12q12); LOC442709 (7q21.13) Note: 
harbours a 21 nt deletion; LOC645693 (15q21.2); 
LOC645715 (3p22.1); LOC646612 (3q22.3) Note: 
lacking about 120 initial codifying nt; LOC728672 
(12p12.3); LOC100128082 (5p12). 
Protein 
Note 
The major form of the protein is 462 residues long, 
composed by three domains, as shown by the diagram, 
that relates also the protein domains (lower bar) with 
mRNA coding exons (upper bar). 
Description 
462 residues, theoretical MW 50140.8 Da, theoretical 
isoelectric point 9.7 eEF1A1 is one of the alpha subunit 
forms of the elongation factor 1 complex, that interacts 
with aminoacylated tRNA and delivers it to the A site 
of the ribosome during the elongation phase of protein 
synthesis. The other form is eEF1A2, encoded by a 
different gene, EEF1A2, located in chromosome 20. 
Expression 
EEF1A1 is constitutively expressed in all tissues, with 
the exception of adult brain, heart and skeletal muscle, 
where EEF1A2 expression is found. 
Localisation 
Mostly cytoplasmic, but also nuclear. 
Function 
Canonical function: aa-tRNA delivery to ribo-some in 
mRNA translation 
The eukaryotic elongation factor 1A (eEF1A1, 
formerly EF-1alpha or eEF1A) protein belongs to the
G-protein superfamily, is one of most abundantly 
expressed protein in mammalian cells and participates 
to mRNA translation. It carries aminoacyl-tRNA (aa-
tRNA) to the A site of the ribosome as a ternary 
complex eEF1A1-GTP-aa-tRNA. In mammalian, it is 
ubiquitously expressed with exception of skeletal 
muscle, heart and brain where during terminal 
differentiation eEF1A2 is produced (Knudsen et al.,
1993). 
Moonlighting functions: cytoskeletal remodel-ling, 
protein folding and degradation, cell signal-ling 
modulation, control of cell growth, apoptosis and cell 
cycle 
1) eEF1A1 and cytoskeletal remodelling. The most 
relevant non canonical function of eEF1A1 is the 
modulation of cytoskeleton organization. eEF1A has 
activity on microtubule severing and bundling. It has a 
specific site to bind actin that is different from that for 
the binding of aa-tRNA (Gross et al., 2005). eEF1A 
binding to F-actin is modulated by Rho/Rho-kinase 
pathway. Phospho-rylation by Rho kinase decreases the 
binding of eEF1A1 to F-actin and F-actin bundling. 
Myosin phosphatase acts in antagonist fashion on 
eEF1A1 to modulate actin cytoskeletal organization 
(Izawa et al., 2000). 
2) eEF1A1 and protein degradation and folding. 
eEF1A controls translational fidelity by binding to 
uncorrectly folded proteins but not to correctly folded 
ones. The uncorrectly folded proteins are then directed 
to degradation pathway (Hotokezaka et al., 2002). 
eEF1A plays a role in recognition and degradation of 
co-translationally damaged and ubiquitylated proteins 
promoting their translocation to proteasome through 
interaction with proteasome subunit Rpt1 (Chuang and 
Madura, 2005). eEF1A exhibits chape-rone-like 
activity by promoting renatura-tion of enzymes such as 
aminoacyl-tRNA synthetases, likely contributing to 
maintain the efficiency of translational machinery 
(Lukash et al., 2004). 
3) eEF1A1 and control of cell cycle, growth and 
death. eEF1A as ribonucleoprotein complex, 
containing a non-coding RNA, binds to and mediates 
activation of heat-shock transcription factor 1 (HSF1) 
to protect the cell from heat-shock (Shamovsky et al., 
2006). Induction of the non-constitutive eEF1A1 
expression in cardiomyocytes as response to lipotoxic 
ER-stress promotes cell death likely by activation of 
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eEF1A1-dependent cytoske-letal modifications 
triggering apoptosis (Borradaile et al., 2006). eEF1A1 
interacts with the HDM2 gene product at a binding site
for eEF1A1 overlaps with that for p53. In normal cels 
eEF1A1 could promote cell apoptosis by preventing 
p53 sequestra-tion by HDM2 (Frum et al., 2007). 
Likely both eEF1A1 and eEF1A2 interacts with the 
zinc finger protein ZPR1 in response to mitogenic 
stimuli, redistributing eEF1A1/2 and ZPR1 in the 
nucleus. This interaction is essential for normal cell 
proliferation and growth. Thus the interaction 
eEF1A1/2-ZPR1 is required for normal cell cycle 
progression (Mishra et al., 2007). eEF1A1 is an 
interactor of Bood POZ containing gene type 2 (BPOZ-
2) that promotes eEF1A1 ubiquitylation and 
degradation via 26S proteasome. BPOZ-2 inhibits GTP 
binding to eEF1A1 thus preventing translation. BOPZ-
2 is transcriptionally activated by Phosphate and Tensin 
homologue deleted on chromosome 10 (PTEN). It has 
been suggested that PTEN exerts growth inhibition 
effects in cells not only by antagonizing PI3K-Akt 
signalling path-way, but also inducing BPOZ-2 
expression to degrade eEF1A1. In this manner, in 
normal cells, the transition from growing to resting 
phases is mediated by BPOZ-2/eEF1A1 interaction, 
thus leading to prevention of translation and induction 
of eEF1A1 degradation by 26S proteasome pathway 
(Koiwai et al., 2008). eEF1A1 is implicated in a novel 
cell cycle check-point to prevent tetraploidy in 
binucleated cells. In tetraploids, cell death, preventing 
aneuploidy malignancies, is mainly controlled in a 
caspase-independent man-ner by the down-regulation 
of eEF1A1 levels. eEF1A1 mRNA accumulates in 
specialized P bodies to reduce the expression of the 
proteins. The prominent signal in the eEF1A1 mRNA 
for its translational repression and degradation is i the 
5'-UTR. Exogenous expression of eEF1A1 inhibits cell 
death in tetraploids. Notably, exogenous expression of 
eEF1A2 whose mRNA 5'-UTR differs from that of 
eEF1A1 inhibits cell death in tetraploids, thus 
suggesting another mechanism by which eEF1A2 could 
promote tumour development (Kobayashi et al., 2009). 
4) eEF1A1 and cell signalling modulation. Besides 
eEF1A2, in adult mouse neurons eEF1A1 is expressed 
too and it is able to regulate the recycle of M4 
muscarinic acetylcholine receptors (mAChR). Thus, 
eEF1A1 plays a role in locomotor activity of neurons 
(McClatchy et al., 2006). eEF1A1 modulates the 
activities of sphingosine kinases (SK1 and SK2). 
Phosphorylated and non-phosphorylated eEF1A1 forms 
interact with phosphoryla-ted and non phosphorylated 
SK1 and SK2 and this results in an increased enzymatic 
activity of both SK1 and SK2. In this respect, 
overexpression of eEF1A1 in quiescent cells has been 
suggested to play a role in oncogenesis by increasing 
SK1 and SK2 activities (Leclercq et al., 2008). eEF1A1 
is involved in the regulation of vascular function 
mediated by TNF-alpha. eEF1A1 binds to 3'-UTR of 
the endothelial nitric oxide synthase (eNOS) to regulate 
post-translational eNOS mRNA stability. In the human 
endothelial cell line HUVEC, TNF-alpha-mediated 
eNOS mRNA destabilization involves eEF1A1 to 
reduce eNOS mRNA levels (Yan et al., 2008). 
Homology 
Highly homologous over the entire length to EEF1A2 
(92% identities);  
Moderately homologous over all three domains, higher 
for the first one, to : 
HBS1L, a member of the GTP-binding protein family 
expressed in erythroid progenitor cells (39% identities); 
GSPT1, a GTP-binding protein involved in G1 to S 
phase transition (38% identities); 
GSPT2, a GTP-binding protein involved in G1 to S 
phase transition (37% identities); 
TUFM, Tu translation elongation factor, mitochon-drial 
(31% identities). 
Implicated in 
Head and neck cancers 
Note 
eEF1A1 overexpression is observed in cisplatin-
resistant human head and neck cancer cell lines 
(Johnsson et al., 2000). 
Breast cancer 
Note 
EEF1A1 was found to be upregulated in invasive breast 
cancer cells derived from snap-frozen adenocarcinoma 
samples suggesting a role in mediating invasive activity 
of cancer cells (Zhu et al., 2003). Treatment of the
breast human cancer cell line MCF-7 with the histone 
deacetylase inhibitor sodium butyrate decreases 
significantly in a dose-dependent manner the eEF1A1 
transcription levels. Thus, overexpression of eEF1A1 
contributes to breast cancer survival (Gonçalves et al., 
2005). 
Tongue squamous cell carcinoma 
Note 
A suggestive down-regulation of EEF1A1 expression 
has been observed in human tongue squamous cell 
carcinoma with positive lympho-nodes and 
extracapsular spread. Thus EEF1A1 down-regulation 
might be involved in the tumour cell progression 
toward the metastasis (Zhou et al., 2006). 
Hepatocarcinoma 
Note 
eEF1A1 overexpression in human hepatocarcinoma 
cell lines correlates with an increase of proliferation 
rate and with the ability to escape apoptosis under 
suboptimal growth conditions. In particular eEF1A1 
overexpression is higher in the more aggressive  
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phenotype cell line JHH6 with respect to the more 
differentiated HepG2 and HuH7 cells (Grassi et al.,
2007). eEF1A1 regulates the half-life of osteopontin 
(OPN) mRNA. eEF1A1 is a trans-acting factor that 
binds to 5'-UTR of OPN. This has strong implications 
in the invasive process as demonstrated in 
hepatocellular carcinoma cells, OPN being the major 
secreted phosphoprotein which is overexpressed by 
tumour cells in advanced metastatic cancer.  
The higher expression of OPN in invasive cancer cells 
is due to the different localization of eEF1A1: in non 
invasive Hep3B cells it is mainly bound to G actin 
whereas in invasive HepG2 type eEF1A1 and G actin 
association is minimal. Thus eEF1A1 is an indirect 
regulator of OPN by affecting the OPN mRNA stability 
through the interaction with G actin. Only F actin-
bound eEF1A1 cannot interact with 5'-UTR of OPN 
(Zhang et al., 2009). 
Testicular germ tumours 
Note 
eEF1A1, as well as eEF1A2, is an interactor of the 
human testis-specific Y-encoded (TSPY) gene. It has 
been demonstrated that the binding to TSPY leads to a 
redistribution of the TSPY-eEF1A1/2 complex in the 
cell with a nuclear co-localization. A role of the TSPY-
eEF1A1/2 complex has been suggested in promoting 
neoplastic transformation and in sustaining cancer cell 
growth in human testicular germ tumours, prostate 




A variant form of eEF1A1 named cervical cancer 
suppressor 3 (CCS-3) lacking the 101 aminoacids at the 
N-terminal region, has been identified as tumour 
suppressor that is present in non-trans-formed human 
cell lines. Its ectopical expression in a cervical tumour 
cell line leads to cell growth inhibition and apoptsis. 
CCS-3 seems to act as a co-transcriptional repressor by 
interacting with the transcriptional regulator PLZF 
(Rho et al., 2006). 
The mRNA of CCS-3 (GenBank Accession AF322220) 
appears to be a fusion product joining the reverse of the 
end portion of the 3' UTR of another product 
(NM_005763, from gene AASS) with most of the 
normal sequence of EEF1A1 mRNA. 
Various tumours including prostate 
adenocarcinoma, colon 
adenocarcinoma, pancreatic cancer and 
gastric cancer 
Note 
A variant form of eEF1A1 lacking 67 aminoacids at the
N-terminal region has been proposed to promote cell 
transformation and to sustain tumour cells viability. I   
has been named prostate inducing gene-1 (PTI-1), also 
known as elongation factor 1A-like 14. Initially 
identified by differential RNA display screening of 
cDNA expression library in the human prostate cancer 
cell line LNCaP, it has been proposed to act as a 
dominant oncogene in human prostatic 
adenocarcinoma. Its mRNA contains a 5'-UTR of 630 
bp that is highly homologous to part of the 23S rRNA 
of Mycoplasma sp. fused to most of the CDS of 
EEF1A1, resulting in the substitution of its first 67 N-
terminal residues with Met-Gln-Ser (Sun et al., 1997; 
Mansilla et al., 2005). Ectopically forced expression of 
PTI-1 in a mouse cell line induces tumours in nude 
mice and antisense PTI-1 molecule can reverse 
malignant phenotype of the transformed cells (Su et al., 
1998). Silencing of PTI-1 by specific RNAi not 
affecting eEF1A1 expression, in a human prostate 
cancer cell line leads to a reduction of cellular growth, 
to the block of cell cycle in G1 phase and to the 
promotion of apoptosis (Yu et al., 2006). It has been 
hypothesized that PTI-1 could promote cell 
transformation by causing translational infidelity being 
in competition with eEF1A1 (Gopalkrishnan et al., 
1999). PTI-1 mRNA is detected only in human cancer 
cells upon Mycoplasma infection. It remains under 
investigation whether PTI-1 can play a role in the 
natural history of human prostatic adenocarcinoma 
upon Mycoplasma infection. The origin of the chimeric 
transcript of PTI-1 remains to be ascertained 
(Scaggiante et al., 2008). PTI-1 mRNA has been 
detected in multidrug-resistance colon cancer cell line 
LoVoDX (Bertram et al., 1998). By using the detection 
of a unique PTI-1 region between the 5'UTR and the 
CDS, PTI-1 mRNA has been found in the human 
pancreatic cancer cell line AsPC-1, in the human 
gastric cancer TMK-1 cells, and in the hepatoma 
Alexander cells, but not in several other pancreatic, 
gastric and hepatoma human cancer cell lines. 
Interestingly, in AsPC-1 cells the down-regulation f 
K-ras mRNA by antisense leads to a reduction of PTI-1 
level. PTI-1 mRNA was detected in three of five 
surgical human specimens of pancreatic cancer 
(Ohnami et al., 1999). 
Cutaneous T-cell lymphoma 
Note 
In human sera derived from Cutaneous T-Cell 
Lymphoma (CTCL) patients one of the new tumour 
antigens was a truncated version of eEF1A1 lacking 77 
aminoacids at N-terminal. 
Leukemia 
Note 
In the promyelocytic human leukemia cells the 
differentiation agent All-Trans-Retinoic Acid (ATRA) 
induces down-regulation of eEF1A1 thus suggesting a 
role in contributing to cancer survival in 
haematopoietic malignancies (Harris et al., 2004). 
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An isoform of eEF1A1 with a more basic isoelectric 
point was identified in human haematopoietic cancer 
cell lines but not in normal lymphocytes raising the 
possibility that post-translation modifications of 
eEF1A1 could be involved in cancer development and 




Characterized by rheumatoid arthritis, spleno-megaly 
and neutropenia. eEF1A1 is found as autoantigen 
(Ditzel et al., 2000). 
Skeletal Muscle Trauma 
Note 
In hypercatabolic traumatized patients eEF1A1 mRNA 
level significantly rose in skeletal muscle as the result 
of injury. eEF1A1 expression correlated with 
overexpression of p66(ShcA) (Bosutti et al., 2007). 
Cell transformation 
Note 
De-regulation of eEF1A1 in rodent cells exposed to 
chemical and physical carcinogens promotes cell 
transformation (Tatsuka et al., 1992). Over-expression 
of eEF1A1 in a non-transformed murine pro-B cell line 
confers selective resistance to apoptosis induced by 
endoplasmic reticulum stress, thus providing long-term 
viability (Talapatra et al., 2000). 
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